Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 12/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15419109 | 0.85 | L3MBTL1 (0.52) | L3MBTL1EGLN1HIF1AMEN1KMT2A | |
| SCHEMBL2384076 | 0.83 | EGLN1 (0.63) | EGLN1HIF1A | |
| SCHEMBL15419094 | 0.83 | L3MBTL1 (0.57) | L3MBTL1EGLN1HIF1AMEN1KMT2A | |
| SCHEMBL12254495 | 0.82 | EGLN1 (0.53) | EGLN1HIF1A | |
| SCHEMBL2382746 | 0.81 | L3MBTL1 (0.55) | L3MBTL1EGLN1HIF1AMEN1KMT2A | |
| SCHEMBL2382749 | 0.81 | L3MBTL1 (0.55) | L3MBTL1EGLN1HIF1AMEN1KMT2A | |
| SCHEMBL15418979 | 0.81 | HIF1A (0.52) | L3MBTL1EGLN1HIF1AMEN1KMT2A | |
| SCHEMBL15419103 | 0.80 | L3MBTL1 (0.42) | L3MBTL1EGLN1HIF1AMEN1KMT2A | |
| SCHEMBL2386112 | 0.80 | EGLN1 (0.51) | EGLN1HIF1A | |
| SCHEMBL2382301 | 0.78 | EGLN1 (0.67) | L3MBTL1EGLN1HIF1AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1960363-B1 | QUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS AND USES THEREOF | AMGEN INC (US) | 2014-01-22 | — | — | EP | claimed |
| US-8017626-B2 | Quinolone based compounds exhibiting, prolyl hydroxylase inhibitory activity, and compositions, and uses thereof | AMGEN INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-20100184763-A1 | QUINOLONE BASED COMPOUNDS EXHIBITING, PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | AMGEN INC. | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184763-A1 | QUINOLONE BASED COMPOUNDS EXHIBITING, PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | EGLN3, HIF1AN, EGLN2 | L3MBTL1 4035/4885EGLN1 6/4885HIF1A 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.